CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd. announced it will hold an extraordinary general meeting of shareholders on November 24, 2026, in Tel-Aviv, Israel. The main agenda item is to approve a change of the company's name to "OptiPhi Computing Ltd." and to amend its governing documents accordingly. Shareholders of record as of November 5, 2026, are eligible to vote, and the Board of Directors recommends approving the proposed name change.

CollPlant Biotechnologies Ltd. announced a significant management change and strategic shift. Yehiel Tal has stepped down as CEO and Interim Chairman, effective immediately, as part of a broader cost-reduction plan. Eran Rotem, previously Deputy CEO and CFO, has been appointed as the new CEO, while retaining his CFO role. The company is also discontinuing its regenerative medicine research and development activities to optimize operating expenses. However, the production and supply of recombinant human collagen (rhCollagen) and rhCollagen-based bioinks to business partners will continue.

CollPlant Biotechnologies Ltd. held an Extraordinary General Meeting of Shareholders on July 29, 2026. During the meeting, the company's shareholders approved the proposal that was brought before them. Details of this proposal were previously outlined in a Form 6-K furnished to the SEC on July 7, 2026.

CollPlant Biotechnologies Ltd. announced an Extraordinary General Meeting of Shareholders to be held on August 18, 2026. Shareholders will vote on two key proposals: a reverse stock split at a ratio of 1-for-8 to 1-for-12 and an amendment to eliminate the par value of the Company's share capital. The reverse split is proposed to help the company regain compliance with Nasdaq's minimum bid price requirement, as its shares were trading at $0.319, below the $1.00 threshold, with a compliance deadline of September 21, 2026.

CollPlant Biotechnologies Ltd. announced an Extraordinary General Meeting of Shareholders (EGM) to be held on July 29, 2026, in Tel-Aviv, Israel. The primary agenda item for the EGM is to approve an increase in the company's authorized share capital from 30,000,000 to 500,000,000 ordinary shares. Shareholders of record as of July 9, 2026, are eligible to vote, and the Board of Directors recommends voting "FOR" the proposal.

CollPlant Biotechnologies Ltd. announced a private placement offering, expecting to raise approximately $2.6 million in gross proceeds. The offering includes 7,647,061 ordinary shares (or pre-funded warrants) and accompanying unregistered series A and B warrants, priced at $0.34 per share and accompanying warrants. The company intends to use the net proceeds for general corporate purposes, working capital, funding research and development programs, and evaluating strategic business combinations.

CollPlant Biotechnologies reported a significant decline in Q1 2026 GAAP revenues to $73,000 from $2.1 million in Q1 2025, primarily due to a non-recurring milestone payment last year, resulting in a net loss of $3.1 million, up from $1.5 million. The company is actively engaged in discussions for potential collaborations in medical aesthetics and advancing its next-generation dermal filler platform, securing a patent in Korea. Additionally, CollPlant has initiated a process to evaluate strategic alternatives to maximize shareholder value, alongside implementing cost-cutting measures including a 50% headcount reduction.